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Objective: Preclinical and observational data suggest that angiotensin converting enzyme inhibitors
(ACEi) and angiotensin receptor blockers (ARBs) may be able to improve physical performance in older
people via direct and indirect effects on skeletal muscle. We aimed to summarize current evidence from
randomised controlled trials in this area.
Design: Systematic review and meta-analysis.
Setting and Participants: Randomized controlled trials enrolling older people, comparing ACEi or ARB to pla-
cebo, usual care or another antihypertensive agent, with outcome data on measures of physical performance.
Methods: We searched multiple electronic databases without language restriction between inception and
the end of February 2020. Trials were excluded if the mean age of participants was <65 years or
treatment was targeting specific diseases known to affect muscle function (for example heart failure).
Data were sought on measures of endurance and strength. Standardized mean difference (SMD) treat-
ment effects were calculated using random-effects models with RevMan software.
Results: Eight trials (952 participants) were included. Six trials tested ACEi, 2 trials tested ARBs. The mean
age of participants ranged from 66 to 79 years, and the duration of treatment ranged from 2 months to
1 year. Trials recruited healthy older people and people with functional impairment; no trials specifically
targeted older people with sarcopenia. Risk of bias for all trials was low to moderate. No significant effect
was seen on endurance outcomes [6 trials, SMD 0.04 (95% CI e0.22 to 0.29); P ¼ .77; I2 ¼ 53%], strength
outcomes [6 trials, SMD e0.02 (95% CI e0.18 to 0.14), P ¼ .83, I2 ¼ 21%] or the short physical performance
battery [3 trials, SMD e0.04 (95% CI e0.19 to 0.11), P ¼ .60, I2 ¼ 0%]. No evidence of publication bias was
evident on inspection of funnel plots.
Conclusions and Implications: Existing evidence does not support the use of ACE inhibitors or angiotensin
receptor blockers as a single intervention to improve physical performance in older people.
 2021 The Authors. Published by Elsevier Inc. on behalf of AMDA e The Society for Post-Acute and
Long-Term Care Medicine. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).ence 13/53/03 funded by the
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es/by/4.0/).Impaired physical performance, exemplified by reduction in
strength and endurance, is commonwith increasing age and with the
multimorbidity that often accompanies age.1 Impaired physical per-
formance leads in turn to a loss of the ability to perform activities of
daily living, a need for care, and is associated with future disability,
hospital admission, longer length of stay, and earlier death.2e4
Although exercise training is well established as a key therapy to
improve physical performance in older people, not all older people are
either willing or able to undertake exercise therapy. Alternative ways
to improve physical performance in older people are therefore
needed.ty for Post-Acute and Long-Term Care Medicine. This is an open access article under
L. Caulfield et al. / JAMDA 22 (2021) 1215e12211216Angiotensin converting enzyme inhibitors (ACEi) and angiotensin
receptor blockers (ARB) are classes of medication that work by either
inhibiting production of angiotensin II or blocking the effect of
angiotensin II at the AT1 receptor. They have a number of beneficial
effects on cardiovascular physiology including improved endothelial
function, reduced myocardial fibrosis, regression of left ventricular
hypertrophy, and improvement of left ventricular systolic function.
Use of these medication classes improves function and prognosis in a
wide range of cardiovascular conditions including heart failure, hy-
pertension, stroke, and ischemic heart disease.5e8
More recently, a number of biological mechanisms have been
elucidated by which these drugs might improve peripheral skeletal
muscle function.9 Angiotensin II has direct deleterious effects on
skeletal muscle structure and function in experimental conditions10,11
and may impair both macrovascular and microvascular endothelial
function, and hence, blood flow in peripheral vascular beds.12 Angio-
tensin II also promotes chronic inflammation,13 which is in turn
thought to be an important driver of sarcopeniadthe age-related loss
of muscle mass and strength that underpins impaired physical per-
formance in many older people. Conversely use of ACEi and ARBs can
ameliorate these deleterious effects in experimental conditions; ACEi
or ARB treatment reduces inflammation and endothelial dysfunction
in hypertension14,15 and can improve skeletal muscle atrophy.16 In
addition, ARBs have been shown to augment the effect of exercise on
suppression of myostatin, a key inhibitor of the hypertrophic response
to exercise.17 Finally, ACEi can improve glucose uptake by skeletal
muscle by augmenting insulin function in peripheral tissues.18
A number of randomized control trials have been conducted to
examine the effects of ACEi and ARBs on skeletal muscle function in
older people. Results have been mixed but only 1 previous systematic
review has attempted to synthesize these data.19 This systematic re-
view was conducted in 2015 and included only 4 studies. Since then, a
number of other studies have been published. The aim of this analysis
was, therefore, to conduct an up-to-date and thorough systematic re-
view of the effect of ACE inhibitors and angiotensin receptor blockers
on both endurance and strength performance in older people.
Methods
The review protocol was prespecified and registered on the
PROSPERO database (registration number CRD42014013398). The re-
view was reported using PRISMA statement guidance.20
Search Strategy and Selection Criteria
We searched electronic databases (Medline, CINAHL, Embase,
Cochrane Central Register of Controlled Trials, Controlled Clinical
Trials.com, and NHS elibrary) between inception and the end of
February 2020. No date or language restrictions were employed. An
example search string is shown in Appendix 1. Reference lists of
included studies were hand-searched for additional candidate trials.
We included randomized controlled trials involving human partici-
pants with a mean age of 65 years or over. Trials had to study ACE in-
hibitors or ARBs, given for a minimum of 4 weeks. Comparators could
include usual care, placebo, or another class of antihypertensive. Co-
interventions were permitted if the co-intervention (eg, exercise
training)wasapplied toboth theACEi/ARBarmand the comparator arm.
We excluded trials performed for specific disease states known to
impairexercisecapacityviamechanismsother thanbyeffectsonskeletal
muscle (for instance ischemic heart disease, heart failure, chronic
obstructive pulmonary disease), which may limit exercise capacity via
cardiorespiratory compromise, and also via a specific type Imuscle fiber
skeletal myopathy.21,22 Trials focusing on hypertensionwere permitted,
as were trials focusing on people with diabetes or obesity. We further
excluded trials where an ACEi was compared with an ARB.Data Collection and Extraction
Two reviewers (L.C. and M.W.) reviewed all titles after deduplica-
tion of the search results. Titles flagged as requiring further scrutiny by
either reviewer had abstracts retrieved. Both reviewers reviewed the
retrieved abstracts, and full text papers were flagged by either
reviewer were retrieved. Papers agreed as eligible by all 3 reviewers
(L.C., P.H., M.W.) were forwarded for data extraction. Data were
extracted using a standard, piloted form. One reviewer (L.C. or P.H.)
extracted data, which was then checked by M.W.
We extracted baseline data on trial populations (including age, sex,
functional status, comorbidities, and blood pressure), intervention
type, dose and duration, and details of cointerventions. We sought a
wide range of measures of physical performance, broadly classified as
measures of endurance (including, but not limited to 6-minute walk
distance, 12-minute walk, cycling time, VO2 max, incremental shuttle
walk test, seated step test, arm curl test, recovery heart rate, or
treadmill endurance time), or measures of strength/power [including,
but not limited to sit-to-stand test, handgrip strength, leg (quadriceps)
strength, timed up and go test (TUG), stride length, short course gait
speed, jump height]. We sought data on the Short Physical Perfor-
mance Battery (SPPB) as a specific outcome. For all outcomes, the
longest available follow-up treatment point was included in analyses
if more than 1 time point during treatment was reported.
Assessing Methodological Quality of Included Studies
Risk of bias for each trial was independently assessed by 2 re-
viewers (L.C. and M.W.) using the following categories: allocation
concealment, description of withdrawals and dropouts, analysis on
intention to treat, participant, healthcare staff and outcome assessor
blinding, and comparability of treatment groups at baseline. Trials
were judged as either as low risk, unclear, or high risk.23 Disagree-
ments were resolved by discussion.
Meta-Analysis
Data were combined in meta-analyses using RevMan 5.3 software
(Cochrane Collaboration, Copenhagen, Denmark) using weighted-
squares methods. Random effects models were used for all analyses
to ensure a conservative approach to calculating 95% confidence
intervals given the likely heterogeneity of interventions and
populations.
For endurance measures, the 6-minute walk distance was used as
the first choice, followed by other walk distance tests, then exercise
time, then other tests (eg, VO2max) if no other data were available.
Similarly, for strength tests, quadriceps strength was used as the first
choice, followed by handgrip strength, then timed up and go or sit to
stand tests. SPPB results were combined in a separate meta-analysis as
these are composite tests of balance, walk speed, and leg strength.
Analyses were reported using standardized mean differences
(SMDs) where more than 1 outcome measure type was combined.
Change scores and standard deviation (SD) of changewere usedwhere
reported; percentage change (and SD of percentage change) was used
if this was available in the absence of raw change scores. Where only
baseline and follow-up data were available, change scores were
calculated as the difference between mean follow-up and mean
baseline scores, and the mean of baseline and follow-up standard
deviation was used as a measure of variance. For crossover trials,
adjustment of the standard error was performed as previously rec-
ommended24 to ensure adequate weighting of the study in the anal-
ysis. Funnel plots were generated and inspected visually for
asymmetry suggesting possible publication bias. Sensitivity analyses
confined to homogenous outcomes were performed, along with an-
alyses using the first available follow-up time point as opposed to the
L. Caulfield et al. / JAMDA 22 (2021) 1215e1221 1217last available follow-up time point to test for early treatment effects
and to mitigate the effect of dropout with time.Results
The de-duplicated search found 510 titles; 6 of thesewere included
in the systematic review, along with 2 other studies found during
hand searching of references. The PRISMA flow diagram is shown in
Figure 1. The 8 studies included a total 952 participants, with mean
ages ranging from 66 to 79 years.
Table 1 shows details of the included studies.25e32 Three trials
included participants with functional impairment, 4 trials included
older people with hypertension or elevated cardiovascular risk, and 1
trial included healthy older men. No trials specifically aimed to recruit
participantswith sarcopenia or frailty. Trial size ranged from 36 to 294,
with four trials enrolling more than 100 participants. The agents
studied varied; ACEi in 6 studies and anARB in only 2 studies. In 2 trials,
an alternative antihypertensivewas used as a comparator; placebowas
used in theother trials. Thedurationof treatment varied from15weeks
to 1 year. Two trials examined the effect of ACEi or ARBs in augmenting
the effect of background exercise training. Supplementary Table 1
shows all outcomes reported for each included trial.Quality Assessment
Supplementary Figure 1 shows the risk of bias assessment for the
included trials. The overall risk of bias was low; trials were blinded
and generally well balanced for baseline characteristics. AllocationDeduplicated tles from search: 
510
Full texts retrieved: 9
Abstracts: 36
Included in review: 8
Full texts included: 6
Fig. 1. PRISMA flow diagram. RCT, randomizeconcealment and randomization methods were unclear or insuffi-
ciently detailed in some trials. Funnel plots for endurance and
strength outcomes are shown in Supplementary Figure 2; these did
not suggest publication bias.Effect on Endurance
Figure 2 shows the pooled effect on endurance. Combining data
from 6 trials (6-minute walk distance in 3, cycle endurance time, 12-
minute walk distance and VO2max in another 3) showed no signifi-
cant effect of ACEi on exercise capacity [standardized mean difference
0.04 (95% CI e0.22 to 0.29); P ¼ .77; I2 ¼ 53%, n ¼ 547]. Confining the
analysis to the 3 trials using 6-minute walk distance also showed no
evidence of benefit [mean difference 5 m (95% CI e26 to 37); P ¼ .74;
I2 ¼ 76%, n ¼ 311]. In both cases, a small beneficial effect size (SMD
>0.2 or 6minutewalk distance>20m33) still lies within the 95% CIs. A
further sensitivity analysis using measurements from baseline and the
first available follow-up time also showed no evidence of benefit [SMD
0.12([95% CI e0.07 to 0.30); P ¼ .23; I2 ¼ 19%, n ¼ 562].Effect on Strength
Figure 3 shows the pooled effect on strength measures. Of the 6
included trials, 4 measured quadriceps strength (by a variety of
different techniques), 1 measured handgrip strength, and 1 measured
the timed up and go test. No significant beneficial treatment effect was
evident [SMDe0.02 (95% CIe0.18 to 0.14), P¼ .83, I2¼ 21%]. Excluding
the cross-over trial29 did not change the results: [SMDe0.02 (0.25 toOmied as not relevant on tle: 
474
Omied:
17 not RCT; 4 in specific 
disease; 2 not comparison of 
ACEi/ARB; 2 no performance 
outcomes; 1 too short a 
duraon; 1 part of another 
trial
Omied:
1 not RCT; 1 not comparison of 
ACEi/ARB; 1 in specific disease
Added from handsearching: 2
d controlled trial; SR, systematic review.
Table 1
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Gerdts 200626 Norway 51 68 49 55‒80 y with hypertension




once daily þ HCTZ if
required
Atenolol 50‒100 mg
once daily þ HCTZ if
required
VO2max Maximum load (W) 1 y
Sumukadas
200727
Scotland 130 79 71 65 and over with
impairment of ADLs
Mean 6MWD 299 m
Median TUAG 13s






Bunout 200928 Chile 120 75 76 70 and over with stage I
hypertension






Mean TUAG 11.3 s
Enalapril 10‒20 mg
once daily þ HCTZ if
required
Nifedipine slow-release












Placebo Rescaled SPPB Handgrip strength 6 mo
Sumukadas
201330



















Scotland 80 78 75 65 and over with >1 self-
reported fall in last 12 mo










































(P = .77) Favors control Favors ACEi/ARB
SMD SMD
X
Fig. 2. Endurance measures.
L. Caulfield et al. / JAMDA 22 (2021) 1215e1221 12190.22); P¼ .89; I2 ¼ 37%, n¼ 471]. When restricting the analysis to only
those trials measuring quadriceps strength, no significant treatment
benefit was seen [mean difference1.1 kg([e2.5 to 0.2); P¼ .11. I2¼ 0%,
n ¼ 376]. A further sensitivity analysis using measurements from
baseline and thefirst available follow-up time also showednoevidence
of benefit [SMD -0.01 (95% CI e0.16 to 0.14); P ¼ .88; I2 ¼ 17%].
Effect on SPPB
Figure 4 shows the pooled effect on the SPPB. Two included trials
measured the SPPB using the standard 12-point scale; 1 trial used a
rescaled approach to maximize the power of the continuous mea-
surement components of the score.29 No significant beneficial treat-
ment effect was evident [SMD e0.04 (95% CI e0.19 to 0.11), P ¼ .60,
I2 ¼ 0%]. Excluding the cross-over trial29 showed similar findings
[mean difference 0.2 points (0.7 to 0.3); P ¼ .34. I2 ¼ 0, n ¼ 267].
The minimum clinically important difference in the SPPB has been
estimated at between 0.5 and 1 point33,34; both of these estimates lie
outside the 95% CIs for the estimated treatment effect in this analysis.
A further sensitivity analysis using measurements from baseline and
the first available follow-up time also showed no evidence of benefit
[SMD 0.03 (95% CI e0.12 to 0.18); P ¼ .70; I2 ¼ 0%]
Discussion
Summary of Evidence
Our systematic review found no evidence of efficacy of ACEi or ARB
in improving either strength or endurance measures of physical per-
formance in older people. Overall trial quality was moderate to good,
but trials were in general small with few trials examining outcomes
beyond 6 months. Heterogeneity was low; there appeared to be no
benefit of ACEi or ARB either alone or in conjunction with exercise
training. No difference was apparent in the efficacy of ACEi compared
with ARBs, although head-to-head comparisons were not included in
this analysis. Our findings are consistent with the previous meta-(P = .28);
(P = .83);
X
Fig. 3. Strengthanalysis conducted in 2015 by Zhou et el19 despite the inclusion of
more trials, more participants, and more detailed analyses.Limitations
There are a number of limitations to our analysis. As with any
systematic review, it is possible that we have omitted relevant liter-
ature although the use of a broad search strategy, no language re-
strictions, and inclusion of studies found by hand searching reduced
the chances of missing significant literature. The scope of our review
was limited to participants without a specific disease or condition
affecting muscle strength. We made this choice in an attempt to focus
on whether ACEi or ARBs might have an effect on impaired physical
performance caused by sarcopenia of age and related problems, rather
than by other skeletal myopathies related to specific disease states.
Although the effect of ACEi or ARBs on physical performance in pa-
tients with heart failure, chronic obstructive pulmonary disease, or
other cardiorespiratory disease is clearly of interest, study of these
conditions with their distinct skeletal myopathy and prominent
cardiorespiratory compromise falls out with the scope of the current
analysis. Studies targeting patients with diabetes and obesity are of
interest given the prominent association between these conditions
and skeletal muscle dysfunction,35,36 but our search did not find
eligible trials with relevant outcomes.
The small number of studies included, and the broad range of
outcomes studied, made combining data inmeta-analysis challenging.
For most outcomes, we had to resort to reporting standardized mean
differences because of this heterogeneity in outcomes. Perhaps the
most important limitation of this review, however, is that none of the
included studies specifically sought to recruit patientswith sarcopenia
as defined by contemporary guidelines. Although some of the studies
undoubtedly included participants with sarcopenia (particularly those
which sought to recruit patients with functional impairment), other
studies aimed to recruit healthy older people. We cannot, therefore,
presume that the lack of effect seen in this analysis necessarily applies








L. Caulfield et al. / JAMDA 22 (2021) 1215e12211220included more women than men; this reflects both the predominance
of women in the oldest old, and the fact that older women are more
likely to have low physical performance. We are not able to examine
any differential effects of ACEi or ARBs on men and women from this
trial-level analysis. Additional limitations include a lack of data on
ARBs that were studied in only 2 trials, and a lack of long-term
outcome data; most studies were confined to less than 6 months
follow-up. It is, therefore, possible that longer term use of ACEi or
ARBs may still yield effects; earlier observational data from Onder
et al37 suggested that differences in walking speed between users and
nonusers of ACEi were evident after 3 years of follow-up, although
more recent observational data did not find any association between
either ACE inhibitor use and grip strength38 or a similar use and other
measures of physical performance.Conclusions and Implications
Implications for Practice
Existing evidence does not support the use of ACEi or ARBs as
stand-alone therapies to improve physical performance in older
people, either with or without a diagnosis of sarcopenia. Although
these agents are generally safe and well tolerated in older people and
are highly effective at improving cardiovascular outcomes, their use in
older people should be restricted to reducing blood pressure, reducing
the risk of cardiovascular events, or to improving symptoms and
function in older people with heart failure.39Implications for Research
Further research in this area should focus on people with a diag-
nosis of sarcopenia made using contemporary criteria such as those
recommended by the European Working Group on Sarcopenia.40
Although it is unlikely that use of ACEi or ARBs as single agents over
the short termwould prevent progression to sarcopenia, a preventive
effect on declines in physical performance over the longer term cannot
be ruled out and long-term follow-up from existing ACEi and ARB
studies could still shed light on this. It is also still possible that com-
bination treatment with these agents and others targeting comple-
mentary biological pathways in sarcopenia could yield benefits,
although the evidence presented in this systematic review did not
support a role in augmenting the effect of exercise. Future studies
should endeavor to use a consistent and limited range of performance
measures; hand grip strength, short physical performance battery, 6-
minute walk, and quadriceps strength would give a set of core out-
comes that would most easily combine with existing trial data, and
would accord with recent recommendations for core outcomes in
sarcopenia trials.41Acknowledgments
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Green: Low risk of bias. Yellow: Unclear risk of bias. Red: High risk of bias
Supplementary Fig. 1. Risk of bias assessment. Low risk of bias (green). Unclear risk of bias (yellow). High risk of bias (red).
Supplementary Fig. 2. Funnel plots for risk of publication bias. (A) Endurance measures. (B) Strength measures.
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Supplementary Table 1
Outcome Measures Collected in Each Included Trial
Endurance Measures Strength Measures
6MWD 12MWD VO2max Maximal load Cycle Exercise Time Grip Quadriceps Strength SPPB TUAG STS
Leonetti 199125 X
Gerdts 200626 X X
Sumukadas 200727 X X X
Bunout 200928 X X X X X
Cesari 201029 X X*
Sumukadas 201330 X X X X
Sumukadas 201831 X X
Heisterberg 201832 X
6MWD, 6-minute walk distance; 12MWD, 12-minute walk distance; STS, sit to stand test; TUAG, timed up and go test; VO2max, maximal oxygen uptake.
*Modified version of SPPB.
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